Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 80

Sort by

Sort Order Select

Meeting Abstracts

1785-PUB: Dyslipidemia Management in Patients with the First Acute Coronary Event—A Retrospective Observational EMR-Based RWE Study

JOHANN CHRISTOPHER, ANKUR GUPTA, BALAJI PAKSHIRAJAN, BHAVESH P. KOTAK, KUMAR GAURAV, RAHUL T. RATHOD, MUJTABA HUSSAIN NAQVI SYED, VASU PRAVEEN C. KANURU, ABHISHEK T

Diabetes 2023;72(Supplement_1):1785-PUB

https://doi.org/10.2337/db23-1785-PUB

Published: 23 June 2023

View article titled, 1785-PUB: Dyslipidemia Management in Patients with the First Acute Coronary Event—A Retrospective Observational EMR-Based RWE Study

Meeting Abstracts

315-OR: Diabetes and Dyslipidemia in Young, a Hidden Pandemic—Real-World Multicentric Study from India

ASHISH K. SAXENA, MEENAKSHISUNDARAM LAKSHMANAN, AASHNA PATIL, NAGENDRA K. SINGH, ANUJ MAHESHWARI, MUKULESH GUPTA, BIJAY PATNI, DINESH KUMAR, VINAYAK S. HIREMATH, S S. DARIYA, SURAJEET K. PATRA, RAKA SHEOHARE, MOHSIN ASLAM, RAMA REGULLA, RAGHUNATH DANTU

Diabetes 2023;72(Supplement_1):315-OR

https://doi.org/10.2337/db23-315-OR

Published: 20 June 2023

View article titled, 315-OR: Diabetes and Dyslipidemia in Young, a Hidden Pandemic—Real-World Multicentric Study from India

Meeting Abstracts

1250-P: Clinical and Demographic Characteristics of Patients with Coexistent Type 2 Diabetes, Hypertension, and Dyslipidemia—Results from the Largest Retrospective EMR Study from India

VIDHYA NATARAJAN, RAJEEV CHAWLA, JAMSHED DALAL, PRAVEEN CHANDRA, VIVEKA KUMAR, VAGEESH AYYAR, RAJESH S. BADANI, MUJTABA HUSSAIN NAQVI SYED, KUMAR GAURAV, GAURI D. DHANAKI, RAHUL T. RATHOD, BHAVESH P. KOTAK

Diabetes 2023;72(Supplement_1):1250-P

https://doi.org/10.2337/db23-1250-P

Published: 20 June 2023

View article titled, 1250-P: Clinical and Demographic Characteristics of Patients with Coexistent Type 2 Diabetes, Hypertension, and Dyslipidemia—Results from the Largest Retrospective EMR Study from India

Meeting Abstracts

480-P: Synergistic Effects of Hyperglycemia and Dyslipidemia on Diabetic Neuropathy—High Glucose Aggravates Oxidized LDL-Induced Schwann Cell Death via Hyperactivation of TLR4

WATARU NIHEI, AYAKO KATO, TATSUHITO HIMENO, MASAKI KONDO, JIRO NAKAMURA, HIDEKI KAMIYA, KAZUNORI SANGO, KOICHI KATO

Diabetes 2023;72(Supplement_1):480-P

https://doi.org/10.2337/db23-480-P

Published: 20 June 2023

View article titled, 480-P: Synergistic Effects of Hyperglycemia and Dyslipidemia on Diabetic Neuropathy—High Glucose Aggravates Oxidized LDL-Induced Schwann Cell Death via Hyperactivation of TLR4

Meeting Abstracts

61-LB: Blood Pressure and Lipid-Lowering Medication Adherence in Young Adults with Youth-Onset Type 2 Diabetes and Hypertension or Dyslipidemia—The TODAY2 iCount Study

PAULA M. TRIEF, RUTH S. WEINSTOCK, BRIAN K. BURKE, HUI WEN, SETH KALICHMAN, JANE D. BULGER, BARBARA J. ANDERSON-THOMAS

Diabetes 2023;72(Supplement_1):61-LB

https://doi.org/10.2337/db23-61-LB

Published: 20 June 2023

View article titled, 61-LB: Blood Pressure and Lipid-Lowering Medication Adherence in Young Adults with Youth-Onset Type 2 Diabetes and Hypertension or Dyslipidemia—The TODAY2 iCount Study

Meeting Abstracts

1629-P: Association between Dyslipidemia and Myosteatosis Evaluated by Abdominal Computed Tomography

HWI SEUNG KIM, HAN NA JUNG, YUN KYUNG CHO, WOO JE LEE, CHANG HEE JUNG

Diabetes 2023;72(Supplement_1):1629-P

https://doi.org/10.2337/db23-1629-P

Published: 20 June 2023

View article titled, 1629-P: Association between Dyslipidemia and Myosteatosis Evaluated by Abdominal Computed Tomography

Meeting Abstracts

1239-P: Predictors for COVID-Severity among Hospitalized Patients with Diabetes in Japan

MAYUMI SHOJI, NAOYA TERAMOTO, AIKO HAYASHI, YUKARI MAEDA, HIDETOSHI OCHIAI, AYANO TSUKAGOSHI, YOSHIRO MAEZAWA, MASAYA KOSHIZAKA, KOUTARO YOKOTE

Diabetes 2022;71(Supplement_1):1239-P

https://doi.org/10.2337/db22-1239-P

Published: 01 June 2022

View article titled, 1239-P: Predictors for COVID-Severity among Hospitalized Patients with Diabetes in Japan

Meeting Abstracts

474-P: Efficacy of Saroglitazar on Diabetes Dyslipidemia with Higher Triglyceride

AJAY SINHA

Diabetes 2022;71(Supplement_1):474-P

https://doi.org/10.2337/db22-474-P

Published: 01 June 2022

View article titled, 474-P: Efficacy of Saroglitazar on Diabetes Dyslipidemia with Higher Triglyceride

Journal Articles

Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia

Noha A. Yousri, Karsten Suhre, Esraa Yassin, Alya Al-Shakaki, Amal Robay, Maha Elshafei, Omar Chidiac, Steven C. Hunt, Ronald G. Crystal, Khalid A. Fakhro

Diabetes 2022;71(2):184–205

https://doi.org/10.2337/db21-0490

Published: 03 November 2021

View article titled, Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia

Meeting Abstracts

119-LB: Increased Adiponectin following Efruxifermin Treatment Is Associated with Improvements in Dyslipidemia, Glucose Metabolism, and Liver Health in a 16-Week, Randomized, Placebo-Controlled NASH Trial

JUAN PABLO FRIAS, ERIK J. TILLMAN, RESHMA SHRINGARPURE, ERICA FONG, BRITTANY DE TEMPLE, TIMOTHY ROLPH, ANDREW CHENG, KITTY YALE, STEPHEN A. HARRISON

Diabetes 2021;70(Supplement_1):119-LB

https://doi.org/10.2337/db21-119-LB

Published: 01 June 2021

View article titled, 119-LB: Increased Adiponectin following Efruxifermin Treatment Is Associated with Improvements in Dyslipidemia, Glucose Metabolism, and Liver Health in a 16-Week, Randomized, Placebo-Controlled NASH Trial

Meeting Abstracts

1000-P: Plasma Water T2 Monitors Cardiometabolic Health and Improves with Lifestyle Modification

DAVID P. CISTOLA, RINKAL PATEL, ERIN CAMPBELL, VIPULKUMAR PATEL, ALOK K. DWIVEDI

Diabetes 2021;70(Supplement_1):1000-P

https://doi.org/10.2337/db21-1000-P

Published: 01 June 2021

View article titled, 1000-P: Plasma Water T2 Monitors Cardiometabolic Health and Improves with Lifestyle Modification

Meeting Abstracts

386-P: Chronic Treatment with the Direct AMPK Activator PXL770 Improves Cardiac, Vascular, and Renal Function in Rodents with Diabetes-Related Cardiorenal Disease

YOHAN STEPHAN, MATTHIEU SOULIÉ, LIONEL NICOL, PASCALE GLUAIS-DAGORN, SOPHIE HALLAKOU-BOZEC, PAUL MULDER

Diabetes 2021;70(Supplement_1):386-P

https://doi.org/10.2337/db21-386-P

Published: 01 June 2021

View article titled, 386-P: Chronic Treatment with the Direct AMPK Activator PXL770 Improves Cardiac, Vascular, and Renal Function in Rodents with Diabetes-Related Cardiorenal Disease

Meeting Abstracts

295-OR: Dyslipidemia and Diabetes in Children and Adolescents with Obesity: A 10-Year Retrospective Study

TOMADER ALI, SARADALEKSHMI RADHA, RADWA HELAL, ESPHIE GRACE FOJAS, SHERIF I. EL-REFER, HANI M. SABBOUR, NADER LESSAN

Diabetes 2021;70(Supplement_1):295-OR

https://doi.org/10.2337/db21-295-OR

Published: 01 June 2021

View article titled, 295-OR: Dyslipidemia and Diabetes in Children and Adolescents with Obesity: A 10-Year Retrospective Study

Meeting Abstracts

439-P: A Promising Regulatory Role for MicroRNA-133b in Controlling Lipid Metabolism and Dyslipidemia Gene Expression in Diabetic Retinopathy: The 1000 Qataromics Cohort

AMMIRA S. AKIL, SUJITHA SUBASH PADMAJEYA, LAILA A. JERMAN, TANWIR HABIB, ALYA AL-KURBI, ELBAY E. ALIYEV, MOHAMMED EL ANBARI, KHALID FAKHRO

Diabetes 2021;70(Supplement_1):439-P

https://doi.org/10.2337/db21-439-P

Published: 01 June 2021

View article titled, 439-P: A Promising Regulatory Role for MicroRNA-133b in Controlling Lipid Metabolism and Dyslipidemia Gene Expression in Diabetic Retinopathy: The 1000 Qataromics Cohort

Journal Articles

CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity

Philippe Zizzari, Rongjun He, Sarah Falk, Luigi Bellocchio, Camille Allard, Samantha Clark, Thierry Lesté-Lasserre, Giovanni Marsicano, Christoffer Clemmensen, Diego Perez-Tilve, Brian Finan, Daniela Cota, Carmelo Quarta

Diabetes 2021;70(2):415–422

https://doi.org/10.2337/db20-0162

Published: 03 November 2020

View article titled, CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity

Journal Articles

Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms

Célia Roger, Chloé Buch, Tania Muller, Julia Leemput, Laurent Demizieux, Patricia Passilly-Degrace, Resat Cinar, Malliga R. Iyer, George Kunos, Bruno Vergès, Pascal Degrace, Tony Jourdan

Diabetes 2020;69(10):2120–2132

https://doi.org/10.2337/db20-0078

Published: 17 July 2020

View article titled, Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms

Meeting Abstracts

169-OR: Differential Effects of Amount, Intensity, and Mode of Exercise Training on the Diabetes Risk Index

LEANNA M. ROSS, CRIS A. SLENTZ, IRINA Y. SHALAUROVA, JAMES D. OTVOS, MARGERY A. CONNELLY, CONNIE W. BALES, JOSEPH A. HOUMARD, WILLIAM E. KRAUS

Diabetes 2020;69(Supplement_1):169-OR

https://doi.org/10.2337/db20-169-OR

Published: 01 June 2020

View article titled, 169-OR: Differential Effects of Amount, Intensity, and Mode of Exercise Training on the Diabetes Risk Index

Meeting Abstracts

579-P: Dyslipidemia in Type 2 Diabetic Mice Is Improved by Targeting Smad3 with a Smad3 Inhibitor SIS3

HUIJUN HE, XR HUANG, RONALD C. MA, HY LAN

Diabetes 2020;69(Supplement_1):579-P

https://doi.org/10.2337/db20-579-P

Published: 01 June 2020

View article titled, 579-P: Dyslipidemia in Type 2 Diabetic Mice Is Improved by Targeting Smad3 with a Smad3 Inhibitor SIS3

Meeting Abstracts

1429-P: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: A 1-Year Update from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)

MIKHAIL N. KOSIBOROD, SUZANNE V. ARNOLD, JAMES DELEMOS, ROBERT S. ROSENSON, CHRISTIE M. BALLANTYNE, YUYIN LIU, KATHERINE E. MUES, SHUSHAMA ALAM, DEEPAK L. BHATT, CHRISTOPHER CANNON

Diabetes 2020;69(Supplement_1):1429-P

https://doi.org/10.2337/db20-1429-P

Published: 01 June 2020

View article titled, 1429-P: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: A 1-Year Update from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)

Meeting Abstracts

1177-P: Impact of Proactive Strategies by a Large Self-Insured Employer on Engagement in the Diabetes Prevention Program (DPP)

LAURA N. MCEWEN, KEVIN JOINER, RACHEL BERGMANS, THOMAS E. HURST, WILLIAM H. HERMAN

Diabetes 2020;69(Supplement_1):1177-P

https://doi.org/10.2337/db20-1177-P

Published: 01 June 2020

View article titled, 1177-P: Impact of Proactive Strategies by a Large Self-Insured Employer on Engagement in the Diabetes Prevention Program (DPP)

NARROW

1785-PUB: Dyslipidemia Management in Patients with the First Acute Coronary Event—A Retrospective Observational EMR-Based RWE Study

315-OR: Diabetes and Dyslipidemia in Young, a Hidden Pandemic—Real-World Multicentric Study from India

1250-P: Clinical and Demographic Characteristics of Patients with Coexistent Type 2 Diabetes, Hypertension, and Dyslipidemia—Results from the Largest Retrospective EMR Study from India

480-P: Synergistic Effects of Hyperglycemia and Dyslipidemia on Diabetic Neuropathy—High Glucose Aggravates Oxidized LDL-Induced Schwann Cell Death via Hyperactivation of TLR4

61-LB: Blood Pressure and Lipid-Lowering Medication Adherence in Young Adults with Youth-Onset Type 2 Diabetes and Hypertension or Dyslipidemia—The TODAY2 iCount Study

1629-P: Association between Dyslipidemia and Myosteatosis Evaluated by Abdominal Computed Tomography

1239-P: Predictors for COVID-Severity among Hospitalized Patients with Diabetes in Japan

474-P: Efficacy of Saroglitazar on Diabetes Dyslipidemia with Higher Triglyceride

Metabolic and Metabo-Clinical Signatures of Type 2 Diabetes, Obesity, Retinopathy, and Dyslipidemia

119-LB: Increased Adiponectin following Efruxifermin Treatment Is Associated with Improvements in Dyslipidemia, Glucose Metabolism, and Liver Health in a 16-Week, Randomized, Placebo-Controlled NASH Trial

1000-P: Plasma Water T2 Monitors Cardiometabolic Health and Improves with Lifestyle Modification

386-P: Chronic Treatment with the Direct AMPK Activator PXL770 Improves Cardiac, Vascular, and Renal Function in Rodents with Diabetes-Related Cardiorenal Disease

295-OR: Dyslipidemia and Diabetes in Children and Adolescents with Obesity: A 10-Year Retrospective Study

439-P: A Promising Regulatory Role for MicroRNA-133b in Controlling Lipid Metabolism and Dyslipidemia Gene Expression in Diabetic Retinopathy: The 1000 Qataromics Cohort

CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity

Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms

169-OR: Differential Effects of Amount, Intensity, and Mode of Exercise Training on the Diabetes Risk Index

579-P: Dyslipidemia in Type 2 Diabetic Mice Is Improved by Targeting Smad3 with a Smad3 Inhibitor SIS3

1429-P: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: A 1-Year Update from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)

1177-P: Impact of Proactive Strategies by a Large Self-Insured Employer on Engagement in the Diabetes Prevention Program (DPP)

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only